GrowthCap is pleased to announce The Top Healthcare Investors of 2025. These investors stand out not only for their ability to identify and scale exceptional companies but also for their significant impact on the health and well-being of broad populations.
Now in our fifth year of running this awards process, we are impressed by the depth and breadth of this year’s nominee pool. Investors are increasingly focusing on specific segments of healthcare while also refining the capabilities they offer to portfolio companies.
This year’s awardees were selected for their deep sector expertise, leadership, and ability to navigate the ever-evolving healthcare landscape. Their areas of focus include healthcare software, medical technologies, biotechnology, healthcare services, the connected patient experience, and other related areas. In addition to their investment acumen, these investors have demonstrated an ability to provide unique strategic and/or operational insights that drive value for their portfolio companies.
Investors were nominated by their firms, portfolio company executives, industry peers, or other leading investors. GrowthCap undertakes a methodical and thorough evaluation process for each nominee, reviewing their investment experience, feedback from industry professionals, and overall consistency.
We would like to thank all those who participated in this year’s process. While many highly impressive individuals were nominated but not selected, they deserve recognition for their valuable contributions to the healthcare industry.
Please join us in recognizing and celebrating the achievements of The Top Healthcare Investors of 2025
Garheng Kong
Firm: HealthQuest Capital
Title: Managing Partner & Founder
Garheng is the Managing Partner and Founder of HealthQuest Capital, a private asset firm that provides growth capital to transformative companies that are improving value in the healthcare system. Prior to founding HealthQuest, Garheng was a partner at Intersouth Partners and Sofinnova Investments, and has also spent time at GlaxoSmithKline and McKinsey, and as the CEO of two healthcare companies. A physician, scientist, and engineer by training, Garheng has over two decades of experience investing in innovative companies in all areas of healthcare and has led over 36 companies to successful exits (IPO and M&A).
Garheng has represented HealthQuest on the board of 28 portfolio companies and presently serves as Lead Director of LabCorp (LH) and on the boards of Xeris Biopharma Holdings (XERS), Be The Match, Duke University Health System, Dell Children’s Foundation, UT President’s Commercial Advisory Board, and the Austin Healthcare Council Board. He is an Aspen Institute Health Innovators Fellow, a Kauffman Fellows Mentor, and a member of YPO.
Garheng received undergraduate degrees in both chemical engineering and biological sciences from Stanford, while on an athletic scholarship, and earned MD, PhD, and MBA degrees from Duke University.
“When I started HealthQuest, it was with the belief that we could make a broader impact on healthcare by investing than I could as an individual physician. While we’re proud to support innovation across areas like medical devices and care delivery, it’s the companies themselves, reaching and improving the lives of millions of patients, that make this work truly meaningful and rewarding. As healthcare continues to evolve, I’m excited for what lies ahead and the opportunity to help navigate this landscape alongside exceptional founders and teams.” – Garheng Kong
Chris Hadley
Firm: Berkshire Partners
Title: Managing Director
Chris Hadley is a Managing Director at Berkshire Partners and a leader within the firm’s healthcare investment team, where he has demonstrated exceptional leadership and strategic acumen over his 27-year tenure with the firm. Known for his unique ability to build trust and foster collaboration, Chris has earned the respect of both peers and portfolio company management teams. Currently, he serves on the boards of five Berkshire portfolio companies, including Ensemble Health Partners, IVC Evidensia, Precision Medical Group, US Anesthesia Partners, and Vital Care Infusion Services, where he plays a pivotal role in guiding their growth and success.
Internally, Chris serves as Chair of the Private Equity Investment Committee and is an active member of the Governance and Policy Committee. Beyond his corporate responsibilities, he is deeply committed to philanthropy, serving as Chairman of the Investment Committee for Dana-Farber Cancer Institute. Additionally, he serves as a trustee for the Dana-Farber Cancer Institute, where he plays a significant role supporting its mission through key guidance and financial oversight.
Chris received a BS from the University of Wisconsin and an MBA from The Wharton School of the University of Pennsylvania.
“This acknowledgment celebrates the tremendous work of Berkshire’s healthcare team and the inspiring leadership across our portfolio companies. It affirms our conviction that strong relationships are key to impactful partnerships, a principle we live by daily. I am grateful for this recognition and proud that Berkshire exemplifies these values in action.” – Chris Hadley
Jeff Haywood
Firm: Spectrum Equity
Title: Managing Director
Jeff Haywood co-leads Spectrum Equity’s healthcare investments, which he’s done with Steve LeSieur since 2015. The firm’s healthcare investments are focused on high-growth software and data services companies across the healthcare continuum.
Jeff currently serves on the boards of Definitive Healthcare (NASDAQ: DH), RxVantage, and VBA. He also led Spectrum’s investment in PWNHealth and subsequent sale to Everlywell, where he continues as a board observer. Jeff’s past investments include GoodRx (NASDAQ: GDRX), Payer Compass (acquired by Zelis Healthcare), Datassential (acquired by New Mountain Capital), Net Health (acquired by The Carlyle Group), Verisys (acquired by Aperture Health), Membersy (now Kleer-Membersy), Passport Health Communications (acquired by Experian), and MedHOK (acquired by Hearst Health). This is Jeff’s fourth year on the GrowthCap Top HealthCare Investors list.
“It’s a privilege to partner with companies that sustainably benefit the healthcare system. The entrepreneurs we support are building lasting solutions that make care more accessible, more affordable, and more effective — and we’re honored to be part of that journey.” – Jeff Haywood
Steve LeSieur
Firm: Spectrum Equity
Title: Managing Director
Steve LeSieur co-leads Spectrum Equity’s investing efforts across healthcare, which he’s done with Jeff Haywood since 2015. The firm’s healthcare investments are focused on high-growth software and data services companies serving all parts of the healthcare continuum.
Steve recently served on the board of GoodRx (NASDAQ: GDRX); past investments include Payer Compass (acquired by Zelis Healthcare), Definitive Healthcare (NASDAQ: DH), MedHOK (acquired by Hearst Health), HealthMEDX (acquired by NetSmart), Passport Health Communications (acquired by Experian), and QTC Management (acquired by Lockheed Martin). This is Steve’s fourth year on the GrowthCap Top HealthCare Investors list.
“We’re proud to support healthcare companies that are improving outcomes and increasing access. It’s inspiring to work alongside leaders who are driving meaningful change in the lives of patients, providers, and communities.” – Steve LeSieur
Dr. Robert Mittendorff, MD
Firm: B Capital
Title: General Partner
Dr. Robert Mittendorff is a General Partner and Head of Healthcare at B Capital, a global investment firm managing over $8B in assets. With nearly two decades of experience in clinical medicine, operational leadership, and venture investing, he leads B Capital’s healthcare strategy, focusing on transformative companies across healthtech, biotech, medtech, and digital health.
Dr. Mittendorff has deployed over $800M in capital across 40+ companies, contributing to five IPOs and five major acquisitions. He was pivotal in launching B Capital’s Healthcare Fund I, raising over $500M in 2023 to support healthcare opportunities across the U.S., Asia, and Europe. He and the team manage a portfolio exceeding $1B.
Before B Capital, Dr. Mittendorff was a Partner at Norwest Venture Partners, co-heading the healthcare practice. His career also includes executive roles at Hansen Medical, portfolio strategy at Merck, and emergency medicine at Kaiser Permanente.
Dr. Mittendorff holds an MD from Harvard Medical School, an MBA from Harvard Business School, and an undergraduate degree in biomedical engineering from Johns Hopkins University. He has trained at Stanford University and completed fellowships with Howard Hughes, MIT, and HBS.
“Healthcare is at a pivotal moment, fueled by the convergence of artificial intelligence, robotics and synthetic biology—technologies that are not only transforming care delivery but also unlocking new pathways for long-term value creation. As both a physician and former healthcare executive, I’ve seen firsthand how these innovations are accelerating drug discovery, streamlining operations and personalizing patient care. At B Capital, we are proud to back the visionary companies driving this transformation across healthtech, digital health, biotech and innovative medtech. This recognition reflects the incredible work of our team, and I’m excited to continue partnering with entrepreneurs who are redefining the future of healthcare.” — Dr. Robert Mittendorff, MD
Jason Shideler
Firm: Madison Dearborn Partners
Title: Partner and Co-Head of the MDP Healthcare team
Jason Shideler is a Partner and Co-Head of the Madison Dearborn Partners’ (“MDP”) Healthcare team.
Jason joined MDP in 2006 as an Associate and re-joined in 2010 after earning his MBA from the Stanford University Graduate School of Business. With 17 years of investment experience, Jason has led or been integral in many of MDP’s key investments. Jason currently serves on the Board of Directors of Performance Health and Intermedia. He formerly served on the Board of Directors of Alcami, Ikaria, Kaufman Hall, Sage Products, and Syntellis Performance Solutions, and was actively involved in MDP’s investment in VWR.
“At MDP, we are constantly looking for innovative ways to drive long-term value alongside market leaders throughout the healthcare industry. In our view, this is done most effectively when we partner in lockstep with exceptional management teams – it’s an honor to work alongside such talented entrepreneurs, CEOs, and their organizations.” – Jason Shideler
Joshua Nelson
Firm: THL Partners
Title: Managing Director, Head of Healthcare
Joshua Nelson is a senior leader at THL, where he heads the firm’s healthcare vertical and serves on both the Operating Committee and Investment Committee.
A driving force behind the expansion of THL’s healthcare franchise, Josh has played a central role in shaping the firm’s Identified Sector Opportunities (ISOs) in areas such as pharma services, bioprocessing, and healthcare IT. Over the past decade, he has built and led a dedicated team of investment professionals and executive partners, while cultivating a deep bench of external advisors. His strategic vision and firmwide leadership have been instrumental in establishing THL as a market leader across these dynamic sectors.
Josh is currently a director of Adare Pharma Solutions, Agiliti, CSafe Global, Hospice Care Holdings, IMO Health, Red Nucleus, Senior Home Care Holdings, and Smile Doctors. His prior directorships include 1-800 CONTACTS, Inc., Curo Health Services, Hawkeye Energy Holdings, Healthcare Staffing Services, Intermedix Corporation, Nextech, Party City, and Syneos Health (formerly inVentiv Health, Inc.).
“Partnering with visionary companies that are improving the way care is delivered—that’s what energizes me. We are proud to help these companies grow and make a lasting impact on the patients and providers they serve.” – Joshua Nelson
Megan Preiner
Firm: THL Partners
Title: Managing Director
As a Managing Director in THL’s healthcare vertical, Megan focuses on the firm’s Identified Sector Opportunities (ISOs) in healthcare services, including pharma Services, bioprocessing, and home-based care. Over the past decade, she has assembled a team of investment professionals and executive partners, and a robust network of third-party advisors, to establish the firm’s industry-leading franchise in these areas.
Megan plays a pivotal role within THL’s broader healthcare investment team, where she is respected not just for her sharp investment acumen and operational expertise but also for her dedication to developing talent. She has guided and influenced the careers of many rising professionals, reinforcing the firm’s strong tradition of excellence and forward-thinking leadership.
Megan is currently a director for several healthcare organizations, including Adare Pharma Solutions, Agiliti, Ingenovis, Red Nucleus, Senior Home Care Holdings, and Smile Doctors. Her prior directorships include CSafe Global and Intermedix Corporation.
“Healthcare is evolving rapidly, and we’re fortunate to work with companies that are leading the charge. From tech-enabled services to smarter care models, the impact is both meaningful and measurable.” – Megan Preiner
Kendall Garrison
Firm: TPG
Title: Partner, Co-Head of Healthcare for TPG Capital
Kendall Garrison is a Partner at TPG based in San Francisco, where he co-leads the healthcare team for TPG Capital, the firm’s US and European private equity business. Kendall serves on the boards of ArchWell Health, BVI Medical, Confluent Medical Technologies, Covetrus, Monogram Health, OneOncology, and Pediatric Associates. He previously served on the boards of Kelsey-Seybold Clinic, Kindred at Home, and Kindred Healthcare, and has also been involved in TPG’s investments in Immucor and Surgical Care Affiliates. Prior to joining TPG in 2008, Kendall worked at Goldman, Sachs & Co. in its investment banking division. Kendall received a BBA with honors from the University of Wisconsin-Madison and an MBA from Harvard Business School.
“Our approach to healthcare investing centers around partnerships with transformative companies that are enabling the delivery of better care to more people at lower costs. We leverage our deep sector expertise to drive enduring growth, collaborating with founders and management teams to advance next-generation treatments, develop innovative healthcare technologies, and deliver more personalized, value-oriented care models that can drive improved outcomes at scale.” – Kendall Garrison
Katherine Wood
Firm: TPG
Title: Partner, Co-Head of Healthcare for TPG Capital
Katherine Wood is a Partner at TPG based in San Francisco, where she co-leads the healthcare team for TPG Capital, the firm’s US and European private equity business. She currently serves on the boards of Surescripts, Nextech, LifeStance Health, Convey, and Ellodi, and was previously on the boards of AskBio, Adare, and Neogene. Katherine is the Co-President of TPG Private Equity Opportunities (T-POP), was involved in founding TPG’s Women’s Affinity Group, and currently serves on the board of the Healthcare Private Equity Association (HCPEA).
Prior to joining TPG in 2009, she worked in healthcare investment banking at Goldman, Sachs & Co. Katherine received a BS with honors in molecular and cell biology from Stanford University, where she was on the varsity field hockey team, and an MBA with distinction from Harvard Business School.
“For decades, TPG has partnered with leading management teams that are addressing the complexities of healthcare through technologies, solutions, and services that increase connectivity and enable greater efficiency and innovation across the system. We strive to be true partners to our companies, helping them navigate complexity, accelerate innovation, and grow into stronger, healthier, and more impactful businesses. We are proud to work with great healthcare companies that are building a more integrated, patient-centric healthcare system.” – Katherine Wood
Ross Stern
Firm: Summit Partners
Title: Managing Director
Ross Stern is a Managing Director on the healthcare & life sciences team at Summit Partners. Since joining the firm in 2009, Ross has built a strong reputation of partnering with high-growth companies across provider-led practice management, value-based care, and technology-driven healthcare services. His investments are focused on companies tackling some of the healthcare system’s most complex challenges. This perspective has helped him to identify innovative growth-stage companies, build credibility and a trusted rapport with executives and management teams, and drive value creation post-closing.
Over the course of his 15-year tenure, Ross has led or played a key role in 14 of Summit’s healthcare investments, representing more than $2.7 billion in invested capital. His investment and board experience spans a diverse range of healthcare services and life sciences companies, including Abode Healthcare (acquired by BrightSpring Health Services), Duly Health and Care (acquired by Ares Management), Fortis Life Sciences, Hallmark Health Care Solutions, LucyRx, My Dentist (acquired by Heartland Dental), Paradigm Outcomes, PharmScript (acquired by UnitedHealth Group), Sound Physicians, Thrive Skilled Pediatric Care, TurningPoint Healthcare Solutions, U.S. Renal Care and VaxCare.
“It’s a privilege to work alongside visionary executives and operators who are reshaping how care is delivered and accessed. I’m proud to support their efforts as they work to build enduring businesses and drive meaningful, lasting improvements across the healthcare sector.” – Ross Stern
Darren Black
Firm: Summit Partners
Title: Managing Director
Darren Black has been an active investor and entrepreneur in the healthcare industry for more than two decades, partnering with over 50 high-growth companies across healthcare services, physician-led practice management, value-based care, managed care, pharmaceutical outsourcing, and technology-enabled healthcare solutions. He joined Summit Partners as a Managing Director in 2013 and has been instrumental in expanding Summit’s healthcare & life sciences investment practice. Darren has distinguished himself with his strategic investment approach, strong work ethic, and extensive network.
Since joining Summit Partners, Darren has led 21 investments representing more than $4.0 billion in invested capital. Darren’s current board directorships include Earned Wealth, Leon Medical Centers, LifeStance Health (NASDAQ: LFST), Paradigm, Sound Physicians, TurningPoint Healthcare Solutions, US Health Partners, U.S. Renal Care, VaxCare, and Veranex. His previous board and investment experience includes Abode Healthcare (acquired by BrightSpring Health Services), ABILITY Network (acquired by Inovalon), Advance Health (acquired by New Mountain Capital), DMG Practice Management Solutions (acquired by Ares Management), HealthSun (acquired by Elevance), InnovaCare Health (acquired by Elevance) and PharmScript (acquired by OptumRx).
“At Summit, we seek out companies that are delivering meaningful, durable, and measurable value to payors, patients, and providers. It’s a privilege to partner with innovative executives who are focused on reshaping care delivery models, expanding access, and building enduring platforms in a dynamic and constantly evolving industry.” – Darren Black
Laura Veroneau
Firm: Optum Ventures
Title: Managing Partner
Laura is a Managing Partner and founding team member of Optum Ventures. Under Laura’s guidance and leadership, Optum Ventures has gained recognition as a leading platform in healthcare investing, now with 75+ portfolio companies and over $2 billion in assets under management. Laura’s experience, which ranges from a healthcare startup to UnitedHealth Group, CVS Health, and Transformation Capital, has enabled Laura to develop a deep understanding of the healthcare system with an eye on how innovation can integrate into and transform the overall industry. Laura received her undergraduate degree in economics and legal studies from Williams College, received an MBA from the MIT Sloan School of Management, and currently sits on the Board of Overseers for Brigham and Women’s Hospital.
Matt Emery
Firm: JMI Equity
Title: Partner
Matt joined JMI in 2006 and focuses on JMI’s investments in software and healthcare IT businesses. In addition to supporting JMI’s current portfolio companies, he also helps to identify and assess potential investment opportunities in high-growth software companies. Matt has held numerous board positions at JMI portfolio companies during his tenure and currently oversees the investments or serves on the boards of CipherHealth, Clio, Jane Software, PointClickCare, and TimelyCare. He played an active role with investments in Axonify (acquired by Luminate Capital Partners), Capsule Tech (acquired by Qualcomm), Healthx (acquired by Zipari), Navicure (acquired by Bain Capital), and Workfront (acquired by Adobe).
Prior to joining JMI, Matt was an analyst in the technology investment banking group at Thomas Weisel Partners and a research associate at Thompson, Siegel & Walmsley. Matt is a CFA charter holder and graduated from the University of Virginia with a BS in commerce.
“It’s an incredible honor to collaborate with top-tier entrepreneurs in software and healthcare IT. I’m excited to partner with both current and future portfolio companies to transform the quality of care and elevate the healthcare experience.” – Matt Emery
Dina Said Dwyer
Firm: Eden Capital
Title: Founder & Managing Partner
Dina Said Dwyer is the Founder, Chief Executive Officer, and Chief Investment Officer of Eden Capital Management LLC, and a member of Eden’s Investment Committee. She has more than twenty years of experience in the private equity industry. Prior to founding Eden, she served as a Managing Director at Unifund SA and was responsible for overseeing Unifund’s private equity portfolio companies. Before Unifund, Dina was an Analyst at the Blackstone Group in New York and trained at the Carlyle Group in London.
She serves on the board of directors of Edcetera, White Cup, and Intelvio, and previously served on the board of directors of Wall Street Prep. Additionally, Dina serves on the Advisory Board of the Children’s Rights Division for Human Rights Watch and is a member of the Board of Advisors of Columbia University’s Mailman School of Public Health.
Dina received a Bachelor of Science degree in finance from The Wharton School of the University of Pennsylvania and an MBA from Columbia Business School.
“Eden Capital partners with founders and management teams to scale private companies at critical inflection points. Through our disciplined value-creation process, we support long-term growth and operational excellence. In healthcare, Eden’s investment strategy is guided by three objectives: enhancing outcomes, increasing operational efficiency, and advancing innovation to strengthen the healthcare ecosystem.” – Dina Said Dwyer
Scott Barclay
Firm: Insight Partners
Title: Managing Director
Scott Barclay is a Managing Director at Insight Partners focused on investments in healthtech. Since joining the firm at the end of 2021, Scott has furthered Insight’s reach into healthcare with investments in mental health companies, healthcare infrastructure platforms, AI healthcare solutions, and more. His Computational Care thesis envisions the future of US and global healthcare built at the intersection of empathy and scalable technology.
Prior to Insight, Scott built his investing career as a healthcare angel investor and advisor (NaviHealth, Doximity, Elation) and, from 2015–2020, as a Partner at DCVC, an early-stage deep tech venture capital firm. Scott’s early career traversed capital markets with Banc of America Securities in Europe and the US, The Boston Consulting Group, and CVS Health. At CVS and then after, Scott helped create and scale the nation’s e-Prescribing ecosystem, running iScribe (acq Allscripts) and as Chief Strategy Officer of Surescripts.
“This recognition reflects the entire Insight Partners team. Not only do we have world-class operational experts across every functional area of a software company, but we’ve also built capabilities specifically for healthcare software companies—from talent, to operationalizing AI at scale, to bespoke Go-To-Market to navigate a huge, broken oligopolistic healthcare system. We’re proud to work alongside ambitious founders who are building higher-quality, lower-cost healthcare solutions that work better for everyone who touches the care journey.” – Scott Barclay
David Q. Anderson
Firm: Ampersand Capital Partners
Title: General Partner
David Q. Anderson is a Boston-based General Partner at Ampersand Capital Partners, where he has been a driving force behind the firm’s investments in the healthcare and life sciences sectors since 2010. With over 20 years of experience in middle-market healthcare investing and consulting, David has identified and led numerous transformative investments, particularly within the CDMO and pharma services spaces. His scientific knowledge, paired with deep investment and operational acumen, has enabled him to guide multiple companies to accelerated growth.
David currently serves on the boards of Anabios, Avid Bioservices, Gannet BioChem, Genezen, StageBio (Chairman), and Vernal Biosciences. His notable healthcare exits include Brammer Bio (acquired by Thermo Fisher Scientific), Arranta Bio (acquired by Recipharm), BioClinica (acquired by Cinven), Cellero (acquired by Charles River Labs) and Vibalogics (acquired by Recipharm). Known for his ability to blend scientific innovation with strategic execution, he has consistently helped to scale operations and facilitate growth opportunities for Ampersand’s life sciences and healthcare companies.
He holds a PhD in tumor immunology from the University of Sheffield, a BSc in cell biology & immunology from the University of Aberdeen, and an MBA from Babson College.
“At Ampersand, our greatest strength, and ultimately our success as a firm, lies in our collaborative, team-based approach. I feel privileged to work alongside some of the most extraordinary scientific leaders redefining what’s possible in life sciences and healthcare. Together, we’re building the next generation of companies that will improve health outcomes and transform lives.” – David Q. Anderson
Brian Peterson
Firm: Silversmith Capital Partners
Title: General Partner
Brian joined Silversmith Capital Partners in 2015 and focuses on investments in healthcare IT & services. Brian is passionate about building relationships and partnering with mission-driven entrepreneurs focused on scaling transformative business models that drive high-quality, cost-effective, and efficient healthcare outcomes through innovative technology and services.
Brian has more than 15 years of experience in healthcare investing and financial services, including leading Silversmith’s investments in Advanced Medical Strategies (AMS), EvolveNXT, and Vastian (fka: MediaLab). His additional investment experience at Silversmith includes Centauri Health Solutions, Iodine Software, LifeStance Health (Nasdaq: LFST), Market Access Transformation (acquired by Genesis Research), Net Health, Nordic Consulting (acquired by Bon Secours Mercy Health), and Sound Physicians.
Brian graduated Phi Beta Kappa with a BBA from the Ross School of Business at the University of Michigan and received his MBA with honors as a Palmer Scholar from The Wharton School of The University of Pennsylvania.
“At Silversmith, we’re proud to partner with entrepreneurs who are scaling exceptional companies and transforming care delivery through innovative solutions. It’s a privilege to support these visionary founders, whose leadership is redefining healthcare, improving outcomes, and building a smarter, more scalable ecosystem.” – Brian Peterson
Adam Feinstein
Firm: Vesey Street Capital Partners
Title: Managing Partner
Adam Feinstein is the Founder & Managing Partner of Vesey Street Capital Partners (VSCP) with 30 years of investment experience exclusively in healthcare services. VSCP is a healthcare services private equity firm focused exclusively on lower middle market buyouts. The firm partners with the founders as the first private equity investor in a company and is also focused on corporate carve-outs. Before founding VSCP, he held leadership roles on Wall Street and in the healthcare industry. He was Senior Vice President of Corporate Development, Strategic Investments, and Office of the CEO at LabCorp, following a successful career as a Managing Director at Lehman Brothers/Barclays Capital.
As Chairman of VSCP’s Investment Committee, Mr. Feinstein actively works with portfolio company executives, sources new investment opportunities, and oversees all firm activities. He serves on numerous boards – Inceptua, Shemmassian Academic Consulting, ComplexCare Solutions, AirSculpt Technologies (NASDAQ: AIRS), ScribeAmerica, Safecor Health, GastroMD, and PathGroup. Previously, he served on the boards of QualityMetric, Imedex, and Surgery Partners (NASDAQ: SGRY).
Mr. Feinstein’s industry influence stems from the deep relationships he built at Lehman Brothers and LabCorp. As a CFA charterholder, he holds a BS in business from the Smith School at the University of Maryland and was part of the inaugural class of Nashville’s Healthcare Council Fellows program.
“Throughout my 30-year career, I have been fortunate to build inner circle relationships with key stakeholders throughout the healthcare services industry. We leverage those networks today to source deals and help our portfolio companies grow at Vesey Street Capital Partners. I am honored that my colleague, Mike Doyle, calls me the ‘Kevin Bacon of the Healthcare PE world.’ I feel this level of experience is a key differentiator.” – Adam Feinstein
Marty Felsenthal
Firm: Health Velocity Capital
Title: Partner
Marty Felsenthal is one of the most tenured growth-stage healthcare investors in the country and has invested exclusively in innovative healthcare software and services companies for more than 28 years. He has led investments in companies such as IVX Health (Linden Capital Partners), TelaDoc (NYSE: TDOC), Change Healthcare (acquired by Emdeon), MDLIVE (Cigna), OnShift (ShiftKey), Aperio (Leica Biosystems), Titan Health (United Surgical Partners), US Renal Care (Leonard Green), Payerpath (Misys/Allscripts), Vantage Oncology (McKesson), NovoLogix (CVS Health), Artera Health, and many others. For the past 15 years, he has served as an adviser to the California Healthcare Foundation Innovation Fund. Marty received his AB from Princeton University and his MBA from the Stanford University Graduate School of Business.
In addition to investing on behalf of traditional institutional limited partners, Health Velocity Capital counts among its limited partner base strategic investors and current and former executives who represent organizations that insure over 180 million Americans, operate more than 1,000 hospitals, provide pharmacy and PBM serves to every American, and sell software to every major payor and provider in the country. Health Velocity Capital works collaboratively with these limited partners in pursuit of its mission: supporting innovators contributing to a more affordable, sustainable, consumer-friendly healthcare system.
“For the past 28 years, it has been a privilege to partner with entrepreneurs such as Doug Ghertner at IVX Health and Change Healthcare, Gui de Zwirek at Artera, Mark Woodka at OnShift, Jason Gorevic at Teladoc, Charles Jones at MDLive, and many others. We have leveraged our deep industry relationships and knowledge to help them drive billions of dollars in collective revenue and build companies that have created entirely new sectors in healthcare. They obviously do the hard work, and we are here to support them as best we can. However, I am incredibly grateful for the opportunity to work alongside them and our strategic investors in pursuit of our mission: helping to build innovators that contribute to a more affordable, sustainable, and consumer-friendly healthcare system.” – Marty Felsenthal
Ezra Mehlman
Firm: Health Enterprise Partners
Title: Managing Partner
Ezra Mehlman is a Managing Partner at Health Enterprise Partners, a HCIT and services-focused growth equity firm whose investors include some of the largest health systems and health plans across the country. Ezra is currently on the board of directors of Kno2, Proven Behavior Solutions, BrentCare Behavioral Health, Aware Recovery Care, and The Intermed Group, and is an observer at Wildflower Health. He previously served on the board of directors of AxiaMed (acquired by Bank of America), Applied Pathways (acquired by AIM Specialty Health, a division of Anthem, Inc.), CenterPointe Behavioral Health System (acquired by Acadia Healthcare), InDemand Interpreting (acquired by Stratus Video/AMN Healthcare), Jvion (acquired by Lightbeam Health Solutions), and Twistle (acquired by Health Catalyst).
Prior to joining the team in 2010, Ezra was a Senior Analyst at the Advisory Board Company (NASDAQ: ABCO), providing best practice consulting and research services to hospitals and health systems. After leaving the Advisory Board Company, Ezra served as a Senior Consultant in the health care practice of Booz Allen Hamilton, focusing on engagements in the provider space.
He sits on the Harvard School of Public Health’s Health Policy and Management Executive Council. He is on the faculty of Columbia Business School. Ezra holds a BA cum laude from Washington University in St. Louis, and an MBA from Columbia Business School.
“Working alongside the HEP team and our portfolio companies over these 15 years has been the privilege of a lifetime. As healthcare organizations face mounting challenges, our core approach—partnering with our industry network to identify investments that directly address their pain points—has proven more vital than ever. I’m grateful to the management teams who navigate these complex waters with us, the LPs who’ve entrusted us with their capital, and my colleagues whose enduring commitment to improving healthcare has been the foundation of our firm’s success.” – Ezra Mehlman
Kapil Desai
Firm: Catalyst Investors
Title: Partner
Kapil Desai joined Catalyst Investors in 2014 and is the youngest Partner in Catalyst’s 25-year history. He leads Catalyst’s healthcare practice, which focuses on software and tech-enabled services that enable the delivery of care, leading to better financial results, more efficient operations, and, most importantly, improved clinical outcomes. Kapil has held several board positions at Catalyst portfolio companies and currently oversees or serves on the boards of CoachCare, Presence, Sevaro Health, and Tava Health, among others.
Prior to joining Catalyst, Kapil worked at Credit Suisse in its investment banking division. Kapil earned a BS in business administration, cum laude, from Georgetown University.
“I come from a family of healthcare providers and greatly admire the profession. At Catalyst Investors, my team is committed to finding the right provider-centric solutions to empower them to focus on what they do best – treat patients. As healthcare continues to transform, we have both the opportunity and responsibility to partner and support visionary entrepreneurs dedicated to positively improving the delivery of care and overall patient experience.” – Kapil Desai
William Dai
Firm: ShangBay Capital
Title: Founding Managing Partner
William Dai is the Founding Managing Partner of ShangBay Capital, a leading early-stage, medtech-focused VC based in Palo Alto, California. Since the inception of ShangBay Capital in 2015, William has led ShangBay to become a successful VC with over 72 portfolio companies to date, alongside multiple successful exits. ShangBay’s investment portfolio includes Ceribell, one of the best medtech IPOs, where ShangBay was the first institutional investor. Additionally, ShangBay has syndicated 26 portfolio companies with major strategics.
Currently, William serves on the boards of directors for Luminopia, Aqua Medical, Meditrina, FemDx, Laplace Interventional, and YorLabs. He has also previously served on the boards of NeuroVasc (acquired in 2019) and Arrinex (acquired by Stryker in 2019). As the Founding Managing Partner at ShangBay Capital, he has been critical in leading and executing investment transactions to drive business success.
William’s prior work experiences span more than 25 years in corporate finance, mergers and acquisitions, and capital markets in both Asia and the U.S. Prior to founding ShangBay Capital, he was the CFO of ShangPharma (NYSE: SHP), Nepstar Corporation (NYSE: NPD), MicroPort Scientific Corporation (HKZ: 00853), and Boston Scientific China. William was also the Head of Business Development for a major pharmaceutical company, where he led M&A initiatives for the Asia Pacific region. Across his distinguished career, William managed and executed business transactions that contributed to the companies’ success. William Dai holds a master’s degree in business administration with an emphasis on finance from Michigan State University.
“It’s exciting to see many great medical technology innovations become realities to improve patient outcomes. I have been very fortunate to be a part of this ecosystem, and I look forward to continuing our commitment to support many great innovative medical technology startups to come.” – William Dai
Mirza Baig
Firm: Aldrich Capital Partners
Title: Co-Founder & Managing Partner
Mirza Baig is Co-Founder and Managing Partner at Aldrich Capital Partners, where he leads the firm’s healthcare investments with a focus on scaling technology-enabled solutions that improve care delivery, coordination, and patient outcomes. Over the past decade, he has partnered with exceptional founders to build market-leading companies that are transforming the U.S. healthcare system, particularly in chronic care management, value-based care, and digital infrastructure for payers and providers.
His current portfolio includes high-impact innovators such as Woundtech, eHealth Technologies, TimeDoc Health, Rhythm Management Group, SpinSci, and Persivia. These companies collectively address some of healthcare’s most urgent challenges. Mirza’s deep understanding of the healthcare landscape stems from his experience as a serial entrepreneur and co-founder of Imaging Advantage, where he scaled the company to over $100 million in run-rate revenue.
Mirza holds an MBA from Harvard Business School and a BA in economics from Cornell University.
“The future of healthcare is built at the intersection of tech, care, and talent. We don’t just invest in innovation—we help build the phenomenal teams that make it real.” – Mirza Baig
Jacqueline Berris
Firm: Composition Capital
Title: Principal
Jacqueline Berris is a Principal at Composition Capital, a recently formed, control-oriented, growth-stage private equity firm. She is responsible for sourcing and analyzing investment opportunities, executing transactions, and leading value creation initiatives. Prior to Composition Capital, Jacqueline was a Vice President within Kayne Anderson’s growth capital strategy.
Jacqueline leads Composition Capital’s healthcare investment efforts and serves on several boards, including two healthcare companies initially backed while at Kayne Anderson: the majority recapitalization of TeleMed2U, a provider-founded virtual specialty care platform, and the growth equity investment in Huddle Up, a tech-enabled services company supporting K–12 students on Individualized Education Plans (IEPs). She is actively involved in Composition’s sub-sector thematic development, with recent focus areas including women’s health, specialty pharma, aesthetic practice management, and holistic chronic care management. Jacqueline works closely with Composition’s operating partners to drive these initiatives and support portfolio value creation. Her passion for healthcare is rooted in working alongside mission-driven founders who are improving access, affordability, and outcomes, and in supporting technologies that modernize the outdated workflows critical to the healthcare system.
“At Composition Capital, we are focused on finding great businesses and people to partner with who are dedicated to innovating and driving positive progress in the healthcare industry. Investing in healthcare technology and tech-enabled services has been a core pillar of our teams’ mandate for over a decade. We love the growth-stage as we believe that is the sweet spot of innovation and adoptable change in healthcare, where we can let founders continue to innovate while we support scaling in parallel.” – Jacqueline Berris
Copyright: The Top Healthcare Investors of 2025 publication is copyrighted material, produced and published by GrowthCap, LLC. For information pertaining to content permissions, please refer to GrowthCap’s award usage regulations.
Disclaimer: The data provided in this publication is for informational purposes only and should not be construed as investment advice, endorsement, nor recommendation. GrowthCap believes the information in this publication to be accurate but does not verify its accuracy independently and does not warrant or guarantee that it is accurate or complete. GrowthCap has no obligation to provide any updates or changes to the information. No investment decisions should be made using this information.
